ß-l-2'-deoxynucleotides for the treatment of resistant HBV strains and combination therapies

摘要

225 -L-2 39 -DESOXINUCLEOSIDS FOR THE TREATMENT OF RESISTANT HBV CURRENDS AND COMBINED THERAPIES ". 225 -L-2 39 -deoxynucleosides have been found to be active against hepatitis B virus, mutation resistant drug A method for treating lamivudine resistant HBV (M552V) in a host is provided, which includes administering a 225 -L-2 39 deoxynucleoside or its salt, ester or prodrug In addition, a method of preventing lamivudine-resistant HBV (MSS2V) mutation from occurring in a single host is provided, which includes administering a deoxynucleoside 225 -L-2 39 or salt thereof, ester or a pharmaceutically acceptable prodrug A method for preventing and / or suppressing the emergence of double HBV mutant (L528M / M552V) in a host is also provided, which includes administering a 225 -L-2 39 - deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug thereof.